A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo

Author(s): Bjornaas MA, Bekken AS, Ojlert A, Haldorsen T, Jacobsen D, et al.


Background: To study mortality rate and causes of death among all hospitalized opioid addicts treated for self-poisoning or admitted for voluntary detoxification in Oslo between 1980 and 1981, and to compare their mortality to that of the general population.

Methods: A prospective cohort study was conducted on 185 opioid addicts from all medical departments in Oslo who were treated for either self-poisoning (n = 93, 1980), voluntary detoxification (n = 75, 1980/1981) or both (n = 17). Their median age was 24 years; with a range from 16 to 41, and 53% were males. All deaths that had occurred by the end of 2000 were identified from the Central Population Register. Causes of death were obtained from Statistics Norway. Standardized mortality ratios (SMRs) were computed for mortality, in general, and in particular, for different causes of death.

Results: During a period of 20 years, 70 opioid addicts died (37.8%), with a standardized mortality ratio (SMR) equal to 23.6 (95% CI, 18.7-29.9). The SMR remained high during the whole period, ranging from 32.4 in the first five-year period, to 13.4 in the last five-year period. There were no significant differences in SMR between self-poisonings and those admitted for voluntarily detoxification. The registered causes of death were accidents (11.4%), suicide (7.1%), cancer (4.3%), cardiovascular disease (2.9%), other violent deaths (2.9%), other diseases (71.4%). Among the 50 deaths classified as other diseases, the category "drug dependence" was listed in the vast majority of cases (37 deaths, 52.9% of the total). SMRs increased significantly for all causes of death, with the other diseases group having the highest SMR; 65.8 (95% CI, 49.9-86.9). The SMR was 5.4 (95% CI, 1.3-21.5) for cardiovascular diseases, and 4.3 (95% CI, 1.4-13.5) for cancer. The SMR was 13.2 (95% CI, 6.6-26.4) for accidents, 10.7 (95% CI, 4.5-25.8) for suicides, and 28.6 (95% CI, 7.1-114.4) for other violent deaths.

Conclusion: The risk of death among opioid addicts was significantly higher for all causes of death compared with the general population, implying a poor prognosis over a 20-year period for this young patient group.

Similar Articles

A 24-year follow-up of California narcotics addicts

Author(s): Hser YI, Anglin D, Powers K

Comparing overdose mortality associated with methadone and buprenorphine treatment

Author(s): Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P

Trends in methadone-related deaths in Zurich

Author(s): Laberke PJ, Bartsch C

Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998

Author(s): Perret G, Déglon JJ, Kreek MJ, Ho A, La Harpe R

Hepatitis after intravenous buprenorphine misuse in heroin addicts

Author(s): Berson A, Gervais A, Cazals D, Boyer N, Durand F, et al.

HIV/AIDS: DHAP Strategic Plan

Author(s): Centers for Disease Control and Prevention

Cutaneous complications among i

Author(s): Ho RC, Ho EC, Mak A

Economic costs of nonmedical use of prescription opioids

Author(s): Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD

Use of street methadone in italian heroin addicts presenting for opioid agonist treatment

Author(s): Maremmani I, Pacini M, Pani PP, Popovic D, Romano A, et al.

BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP

Author(s): Lingford-Hughes AR, Welch S, Peters L, Nutt DJ; British Association for Psychopharmacology, Expert Reviewers Group

Clinical pharmacology of buprenorphine: ceiling effects at high doses

Author(s): Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE

Naloxone treatment in opioid addiction: the risks and benefits

Author(s): van Dorp E, Yassen A, Dahan A

Effects of buprenorphine/naloxone in opioid-dependent humans

Author(s): Stoller KB, Bigelow GE, Walsh SL, Strain EC

Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse

Author(s): Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR

Abuse of prescription medicines in southwestern France

Author(s): Baumevieille M, Haramburu F, Begaud B

An injection depot formulation of buprenorphine: extended bio-delivery and effects

Author(s): Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE

Buprenorphine injection in Melbourne, Australia--an update

Author(s): Aitken CK, Higgs PG, Hellard ME

Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users

Author(s): Alho H, Sinclair D, Vuori E, Holopainen A

Buprenorphine: how to use it right

Author(s): Johnson RE, Strain EC, Amass L

Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans

Author(s): Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, et al.

Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers

Author(s): Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ

The effects of buprenorphine in buprenorphine-maintained volunteers

Author(s): Strain EC, Walsh SL, Preston KL, Liebson IA, Bigelow GE

Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia

Author(s): Vicknasingam B, Mazlan M, Schottenfeld RS, Chawarski MC

The emerging buprenorphine epidemic in the United States

Author(s): Wish ED, Artigiani E, Billing A, Hauser W, Hemberg J, et al.

Clinician beliefs and attitudes about buprenorphine/naloxone diversion

Author(s): Schuman-Olivier Z, Connery H, Griffin ML, Wyatt SA, Wartenberg AA, et al.

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone

Author(s): Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, et al.

Prescription opioid abuse among enrollees into methadone maintenance treatment

Author(s): Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, et al.

Abuse of buprenorphine in the United States: 2003-2005

Author(s): Smith MY, Bailey JE, Woody GE, Kleber HD

Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers

Author(s): Schuman-Olivier Z, Albanese M, Nelson SE, Roland L, Puopolo F, et al.

Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users

Author(s): Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND

Crowdsourcing black market prices for prescription opioids

Author(s): Dasgupta N, Freifeld C, Brownstein JS, Menone CM, Surratt HL, et al.

Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment

Author(s): Astals M, Domingo-Salvany A, Buenaventura CC, Tato J, Vazquez JM, et al.

Post-marketing surveillance of methadone and buprenorphine in the United States

Author(s): Dasgupta N, Bailey EJ, Cicero T, Inciardi J, Parrino M, et al.

Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland

Author(s): Gwin Mitchell S, Kelly SM, Brown BS, Schacht Reisinger H, Peterson JA, et al.

The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand

Author(s): Robinson GM, Dukes PD, Robinson BJ, Cooke RR, Mahoney GN

Epidemiological trends in abuse and misuse of prescription opioids

Author(s): Spiller H, Lorenz DJ, Bailey EJ, Dart RC

From research to the real world: buprenorphine in the decade of the Clinical Trials Network

Author(s): Ling W, Jacobs P, Hillhouse M, Hasson A, Thomas C, et al.

Buprenorphine abuse: report from India

Author(s): Chowdhury AN, Chowdhury S

The profile of injection drug users in Chennai, India: identification of risk behaviours and implications for interventions

Author(s): Solomon SS, Desai M, Srikrishnan AK, Thamburaj E, Vasudevan CK, et al.

Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland

Author(s): Genberg BL, Gillespie M, Schuster CR, Johanson CE, Astemborski J, et al.

The use of buprenorphine and temazepam by drug injectors

Author(s): Lavelle TL, Hammersley R, Forsyth A

French field experience with buprenorphine

Author(s): Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J

Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey

Author(s): Boeuf O, Lapeyre-Mestre M; French Network of Centers for Evaluation and Information Pharmacodependence (CEIP)

Falsified or forged medical prescriptions as an indicator of pharmacodependence: a pilot study

Author(s): Lapeyre-Mestre M, Damase-Michel C, Adams P, Michaud P, Montastruc JL

Injecting misuse of buprenorphine among French drug users

Author(s): Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP

[Infectious complications and misuse of high-dose buprenorphine]

Author(s): Cazorla C, Grenier de Cardenal D, Schuhmacher H, Thomas L, Wack A, et al.

Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine

Author(s): Pradel V, Frauger E, Thirion X, Ronfle E, Lapierre V, et al.

Practical reflections on the diversion of drugs

Author(s): Bouley M, Viriot E, Barache D

Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey

Author(s): Curcio F, Franco T, Topa M, Baldassarre C; Gruppo Responsabili UO Sert T

Association between gene variants and response to buprenorphine maintenance treatment

Author(s): Gerra G, Somaini L, Leonardi C, Cortese E, Maremmani I, et al.

Causes of death in a cohort treated for opioid dependence between 1985 and 2005

Author(s): Degenhardt L, Larney S, Randall D, Burns L, Hall W

Increase in unintentional medication overdose deaths: Oklahoma, 1994-2006

Author(s): Piercefield E, Archer P, Kemp P, Mallonee S

Fatal poisoning in drug addicts in the Nordic countries in 2007

Author(s): Simonsen KW, Normann PT, Ceder G, Vuori E, Thordardottir S, et al.

Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children

Author(s): Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR, et al.